These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24175724)

  • 21. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
    Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
    J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Angiogenesis suppressing therapy applied to malignant glioma].
    Takano S
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):941-7. PubMed ID: 19579331
    [No Abstract]   [Full Text] [Related]  

  • 25. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current status of antiangiogenic therapies for glioblastomas.
    Arrillaga-Romany I; Reardon DA; Wen PY
    Expert Opin Investig Drugs; 2014 Feb; 23(2):199-210. PubMed ID: 24320142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
    Lucio-Eterovic AK; Piao Y; de Groot JF
    Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiangiogenic therapies for high-grade glioma.
    Norden AD; Drappatz J; Wen PY
    Nat Rev Neurol; 2009 Nov; 5(11):610-20. PubMed ID: 19826401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells.
    Mesti T; Bouchemal N; Banissi C; Triba MN; Marbeuf-Gueye C; Cemazar M; Moyec LL; Carpentier AF; Savarin P; Ocvirk J
    Radiol Oncol; 2018 Nov; 52(4):392-398. PubMed ID: 30511933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
    Jansen M; de Witt Hamer PC; Witmer AN; Troost D; van Noorden CJ
    Brain Res Brain Res Rev; 2004 Jul; 45(3):143-63. PubMed ID: 15210301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
    Wick W; Wick A; Weiler M; Weller M
    Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question.
    Koukourakis GV
    Recent Pat Inflamm Allergy Drug Discov; 2012 Jan; 6(1):70-7. PubMed ID: 22022926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The emerging role of anti-angiogenic therapy for malignant glioma.
    Reardon DA; Desjardins A; Rich JN; Vredenburgh JJ
    Curr Treat Options Oncol; 2008 Feb; 9(1):1-22. PubMed ID: 18256938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiogenesis and antiangiogenic therapy for malignant gliomas.
    Takano S; Kamiyama H; Tsuboi K; Matsumura A
    Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-angiogenic therapy for malignant glioma].
    Nagane M
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):141-7. PubMed ID: 24743191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M
    FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D ΔR2-μMRA.
    Lin CY; Siow TY; Lin MH; Hsu YH; Tung YY; Jang T; Recht L; Chang C
    Angiogenesis; 2013 Oct; 16(4):785-93. PubMed ID: 23736837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.